SCYNEXIS, Inc. – NASDAQ:SCYX

Add to watchlist

$0.783

-0.21

-21.69%

Market open

Closed in about 1 hour

-54.59%

month

-54.59%

quarter

-49.80%

year

Market Cap	37.61M
Enterprise value	106.88M

P/E	-2.27
EV/Sales	15.05
EV/EBITDA	-1.45
Price/Sales	19.50
Price/Book	42.83
PEG ratio	0.12
EPS	2.00

Revenue	140.38M
EBITDA	72.86M
Income	101.32M
Revenue Q/Q	21.50%
Revenue Y/Y	2436.77%

Profit margin	-1149.2%
Oper. margin	-1791.76%
Gross margin	87.73%
EBIT margin	-1791.76%
EBITDA margin	51.9%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

SCYNEXIS, Inc. (NASDAQ:SCYX): Profit margin
Jun 2023	131.45M	122.26M	93.01%
Sep 2023	1.76M	-1.75M	-99.77%
Dec 2023	5.79M	-19.58M	-337.86%
Mar 2024	1.37M	411K	29.93%

SCYNEXIS Financials Estimate

Q Y

SCYNEXIS, Inc. (NASDAQ:SCYX): Analyst Estimates
Sep 2025	1.72M	-5.58M	-323.08%
Oct 2025	1.72M	-7.28M	-421.69%
Dec 2025	42.47M	0
Dec 2025	56.22M	44.92M	79.9%

Analysts Price target
Financials & Ratios estimates

SCYNEXIS, Inc. (NASDAQ:SCYX): Debt to assets
Jun 2023	154856000	61.77M	39.89%
Sep 2023	148546000	56.55M	38.07%
Dec 2023	128412000	55.45M	43.18%
Mar 2024	118254000	44.14M	37.33%

SCYNEXIS, Inc. (NASDAQ:SCYX): Cash Flow
Jun 2023	74.39M	-6.38M	-36.64M
Sep 2023	12.41M	-26.34M	34K
Dec 2023	-7.73M	-2.15M	-135K
Mar 2024	-4.00M	5.45M	-15K

SCYNEXIS alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

SCYNEXIS, Inc. (NASDAQ:SCYX): Employee count
Aug 2023	36
Sep 2023	36
Oct 2023	36
Nov 2023	36
Dec 2023	36
Jan 2024	36
Feb 2024	36
Mar 2024	36
Apr 2024	36
May 2024	29
Jun 2024	29
Jul 2024	29

SCYNEXIS
Hedge Funds Holdings Q1 2023

20.46% -12.94%

of SCYX is owned by hedge funds

33 -8

hedge funds hold SCYX stock

8.72M -7.14M

shares is hold by hedge funds

SCYX hedge funds holdings changes

SCYNEXIS, Inc. (NASDAQ:SCYX): Insider trades (number of shares)
Period	Buy	Sel
Apr 2022	78500	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	26 Apr 2022	SUKENICK SCOTT officer: General Counsel officer: General Counsel	Common Stock	3,500	$3	$10,500
Purchase	26 Apr 2022	TAGLIETTI MARCO director, officer..	Common Stock	75,000	$3	$225,000
Sale	22 Jan 2021	PERCEPTIVE ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	319,000	$8.56	$2,729,045
Sale	22 Jan 2021	PERCEPTIVE ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	319,000	N/A	N/A
Sale	21 Jan 2021	PERCEPTIVE ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	95,000	N/A	N/A
Sale	20 Jan 2021	PERCEPTIVE ADVISORS LLC 10 percent owner 10 percent owner	Common Stock	185,000	N/A	N/A
Purchase	21 Dec 2020	SUKENICK SCOTT officer: General Counsel officer: General Counsel	Common Stock	1,600	N/A	N/A
Purchase	21 Dec 2020	ANGULO GONZALEZ DAVID officer: Chief Me..	Common Stock	1,600	N/A	N/A
Purchase	21 Dec 2020	FRANCOIS ERIC officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	600	N/A	N/A
Purchase	21 Dec 2020	TAGLIETTI MARCO director, officer..	Common Stock	40,000	N/A	N/A

Status	Patent	Filling date	Issue date
Application	Application ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION Filling date: 12 May 2020 Issue date: 7 Jul 2022	12 May 2020	7 Jul 2022
Application	Application ANTIFUNGAL AGENTS USED IN COMBINATION Filling date: 10 Aug 2021 Issue date: 30 Jun 2022	10 Aug 2021	30 Jun 2022
Application	Application TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OF FUNGAL OSTEO-ARTICULAR INFECTIONS Filling date: 30 Jan 2020 Issue date: 21 Apr 2022	30 Jan 2020	21 Apr 2022
Application	Application NOVEL SALTS AND POLYMORPHS OF SCY-078 Filling date: 29 Jan 2021 Issue date: 23 Dec 2021	29 Jan 2021	23 Dec 2021
Grant	Grant Utility: Salts and polymorphs of SCY-078 Filling date: 11 Jun 2019 Issue date: 23 Feb 2021	11 Jun 2019	23 Feb 2021
Application	Application ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH Filling date: 31 Jul 2018 Issue date: 17 Dec 2020	31 Jul 2018	17 Dec 2020
Application	Application INJECTABLE COMPOSITIONS OF TRITERPENOID ANTIFUNGALS ENCAPSULATED IN LIPOSOMES Filling date: 21 Dec 2018 Issue date: 29 Oct 2020	21 Dec 2018	29 Oct 2020
Application	Application NOVEL SALTS AND POLYMORPHS OF SCY-078 Filling date: 11 Jun 2019 Issue date: 28 Nov 2019	11 Jun 2019	28 Nov 2019
Grant	Grant Utility: Salts and polymorphs of SCY-078 Filling date: 28 Nov 2018 Issue date: 6 Aug 2019	28 Nov 2018	6 Aug 2019

SCYNEXIS
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 9 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 15 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 12 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 29 Mar 2022	Q4 2021 Earnings Call Transcript

SCYX earnings call transcripts

SCYNEXIS
Executives

Insider	Age	Since	Compensation
Dr. Marco Taglietti M.D. (1960) Chief Executive Officer, Pres & Director	65		$991,270
Mr. David Gonzalez Angulo (1965) Chief Medical Officer	60		$709,660

SCYNEXIS
Latest News

Wednesday, 6 November 2024
16:30	SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Thursday, 10 October 2024
08:00	SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit	globenewswire.com
Thursday, 3 October 2024
08:00	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024	globenewswire.com
Tuesday, 27 August 2024
08:00	SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Thursday, 8 August 2024
16:30	SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Tuesday, 23 July 2024
07:00	SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports	globenewswire.com
Monday, 22 July 2024
06:24	3 Stocks Under $10 With the Potential for Massive Gains	investorplace.com
Thursday, 11 July 2024
07:00	3 Dirt-Cheap Drug Developers With Blockbuster Potential	investorplace.com
Monday, 1 July 2024
14:18	7 Undervalued Biotech Stocks to Buy for Big-Time Returns	investorplace.com
Friday, 31 May 2024
11:50	Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025	investorplace.com
Thursday, 23 May 2024
06:42	3 Stocks Under $10 With Mammoth Growth Prospects	investorplace.com
Wednesday, 8 May 2024
16:30	SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update	globenewswire.com
Tuesday, 30 April 2024
16:05	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)	globenewswire.com
Tuesday, 9 April 2024
16:05	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)	GlobeNewsWire
Friday, 5 January 2024
08:30	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy	GlobeNewsWire
Monday, 18 December 2023
18:46	Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'	Seeking Alpha
Tuesday, 26 September 2023
19:54	Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)	Seeking Alpha
Monday, 4 September 2023
15:02	SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why	Zacks Investment Research
Monday, 28 August 2023
22:17	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now	InvestorPlace
08:00	SCYNEXIS to Participate in September Investor Conferences	GlobeNewsWire
Friday, 19 May 2023
16:57	Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating	Seeking Alpha
09:22	WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens	Newsfile Corp
Thursday, 11 May 2023
09:56	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Thursday, 13 April 2023
08:30	SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark	GlobeNewsWire
Friday, 31 March 2023
13:47	Scynexis (SCYX) Inks Antifungal Drug Deal With GSK	Zacks Investment Research
11:47	Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell	Seeking Alpha
06:00	Penny Stocks: Technical Approach to Finding Opportunities	PennyStocks
Thursday, 30 March 2023
10:26	Why Is Scynexis (SCYX) Stock Up 69% Today?	InvestorPlace
Wednesday, 9 November 2022
22:52	SCYNEXIS, Inc. (SCYX) Q3 2022 Earnings Call Transcript	Seeking Alpha
09:47	Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 2 Apr 2024

Scynexis: Update Following Restructuring Of GSK Deal
Seeking Alpha 18 Dec 2023

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
Seeking Alpha 26 Sep 2023

Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)
Seeking Alpha 21 May 2023

Buy Cidara Therapeutics For Data Readout And European Foothold
Seeking Alpha 19 May 2023

Scynexis: A Disappointing Q1 Earnings And Cooling GSK Catalyst - We Maintain Neutral Rating
Seeking Alpha 31 Mar 2023

Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell
Seeking Alpha 30 Oct 2022

Scynexis: No Compelling Reason To Invest
Seeking Alpha 26 Aug 2022

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Seeking Alpha 7 Mar 2022

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Seeking Alpha 27 Jul 2021

Scynexis: Leading The Yeast Infection Treatment Industry

Frequently Asked Questions (FAQ)

What's the price of SCYNEXIS stock today?

One share of SCYNEXIS stock can currently be purchased for approximately $0.78.
When is SCYNEXIS's next earnings date?

Unfortunately, SCYNEXIS's (SCYX) next earnings date is currently unknown.
Does SCYNEXIS pay dividends?

No, SCYNEXIS does not pay dividends.
How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of 37.61M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2652.72% to 140.14M US dollars.
What is SCYNEXIS's stock symbol?

SCYNEXIS, Inc. is traded on the NASDAQ under the ticker symbol "SCYX".
What is SCYNEXIS's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of SCYNEXIS?

Shares of SCYNEXIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the following people:
- Dr. Marco Taglietti M.D. Chief Executive Officer, Pres & Director(age: 65, pay: $991,270)
- Mr. David Gonzalez Angulo Chief Medical Officer(age: 60, pay: $709,660)
How many employees does SCYNEXIS have?

As Jul 2024, SCYNEXIS employs 29 workers, which is 19% less then previous quarter.
When SCYNEXIS went public?

SCYNEXIS, Inc. is publicly traded company for more then 11 years since IPO on 2 May 2014.
What is SCYNEXIS's official website?

The official website for SCYNEXIS is scynexis.com.
Where are SCYNEXIS's headquarters?

SCYNEXIS is headquartered at 1 Evertrust Plaza, Jersey City, NJ.
How can i contact SCYNEXIS?

SCYNEXIS's mailing address is 1 Evertrust Plaza, Jersey City, NJ and company can be reached via phone at +20 18845485.

SCYNEXIS, Inc.

scynexis.com

Exchange:

NASDAQ

Full time employees:

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

+20 18845485

1 Evertrust Plaza
Jersey City, NJ 07302-6548

CIK: 0001178253
ISIN: US8112922005
CUSIP: 811292200